{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:54:46Z","timestamp":1761897286755,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bbmt.2020.03.028","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T02:18:19Z","timestamp":1587349099000},"page":"1414-1424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma"],"prefix":"10.1016","volume":"26","author":[{"given":"Sarah A.","family":"Holstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera J.","family":"Suman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouros","family":"Owzar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Santo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Don M.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Isola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Linker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbmt.2020.03.028_bib0001","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/asheducation-2016.1.504","article-title":"Role of stem cell transplant and maintenance therapy in plasma cell disorders","volume":"2016","author":"McCarthy","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"26","key":"10.1016\/j.bbmt.2020.03.028_bib0002","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.bbmt.2020.03.028_bib0003","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bbmt.2020.03.028_bib0004","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.13994","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.03.028_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8000","article-title":"Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM trial)","volume":"34","author":"Cavo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bbmt.2020.03.028_bib0006","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bbmt.2020.03.028_bib0007","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbmt.2020.03.028_bib0008","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bbmt.2020.03.028_bib0009","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1182\/blood-2008-07-168823","article-title":"Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma","volume":"112","author":"Moreau","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbmt.2020.03.028_bib0010","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bbmt.2020.03.028_bib0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V114.22.51.51","article-title":"Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma: an interim analysis of the German DSMM V Trial","volume":"114","author":"Knop","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bbmt.2020.03.028_bib0012","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.bbmt.2020.03.028_bib0013","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1182\/blood-2011-03-339945","article-title":"Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma","volume":"117","author":"Giaccone","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bbmt.2020.03.028_bib0014","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up","volume":"29","author":"Bjorkstrand","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.bbmt.2020.03.028_bib0015","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bbmt.2020.03.028_bib0016","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.028_bib0017","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bbmt.2020.03.028_bib0018","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bbmt.2020.03.028_bib0019","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2006-07-036848","article-title":"Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning","volume":"109","author":"Crawley","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbmt.2020.03.028_bib0020","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bbmt.2020.03.028_bib0021","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","article-title":"Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma","volume":"10","author":"Kroger","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bbmt.2020.03.028_bib0022","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05513.x","article-title":"Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma","volume":"129","author":"Kroger","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.bbmt.2020.03.028_bib0023","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/028418600750063596","article-title":"Allogeneic haemopoietic stem cell transplantation for multiple myeloma or plasma cell leukaemia using fractionated total body radiation and high-dose melphalan conditioning","volume":"39","author":"Russell","year":"2000","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.bbmt.2020.03.028_bib0024","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.03.028_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2307\/2531951","article-title":"Confidence Intervals for a binomial parameter based on multistage tests","volume":"43","author":"Duffy","year":"1987","journal-title":"Biometrics"},{"issue":"9","key":"10.1016\/j.bbmt.2020.03.028_bib0026","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.028_bib0027","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2020.03.028_bib0028","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.028_bib0029","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.028_bib0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bbmt.2020.03.028_bib0031","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bbmt.2020.03.028_bib0032","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/bmt.2014.310","article-title":"Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial","volume":"50","author":"Iacobelli","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.028_bib0033","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2012.142","article-title":"Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory\/relapsed myeloma patients","volume":"48","author":"Kroger","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.bbmt.2020.03.028_bib0034","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bbmt.2020.03.028_bib0035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bmt.2012.173","article-title":"Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment","volume":"48","author":"Armeson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.028_bib0036","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-6-2","article-title":"Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Kharfan-Dabaja","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.028_bib0037","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbmt.2017.10.024","article-title":"Autologous\/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival","volume":"24","author":"Htut","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bbmt.2020.03.028_bib0038","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3109\/10428194.2016.1154958","article-title":"Tandem autologous versus autologous\/allogeneic transplantation for multiple myeloma: propensity score analysis","volume":"57","author":"Kawamura","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.028_bib0039","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/bmt.2015.45","article-title":"Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma","volume":"50","author":"Sahebi","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bbmt.2020.03.028_bib0040","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"issue":"29","key":"10.1016\/j.bbmt.2020.03.028_bib0041","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bbmt.2020.03.028_bib0042","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2020.03.028_bib0043","first-page":"401","article-title":"Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02\/HO95 study","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bbmt.2020.03.028_bib0044","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.03.028_bib0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-018-0553-8","article-title":"Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017","volume":"18","author":"Yin","year":"2018","journal-title":"Cancer Cell Int"},{"issue":"11","key":"10.1016\/j.bbmt.2020.03.028_bib0046","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41375-019-0537-2","article-title":"Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis","volume":"33","author":"Knop","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bbmt.2020.03.028_bib0047","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.leu.2404459","article-title":"Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion","volume":"21","author":"Sagaster","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.028_bib0048","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","article-title":"Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma","volume":"19","author":"Kroger","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bbmt.2020.03.028_bib0049","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3324\/haematol.2011.042713","article-title":"Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"96","author":"Roos-Weil","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.bbmt.2020.03.028_bib0050","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.bbmt.2016.08.024","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features","volume":"22","author":"Rasche","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bbmt.2020.03.028_bib0051","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2016.03.001","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: impact of disease risk and post allograft minimal residual disease on survival","volume":"16","author":"Dhakal","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.028_bib0052","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bbmt.2020.03.028_bib0053","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2003-12-4435","article-title":"Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation","volume":"103","author":"Kr\u00f6ger","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbmt.2020.03.028_bib0054","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.bbmt.2019.01.009","article-title":"Comparison of outcomes of allogeneic hematopoietic cell transplantation for multiple myeloma using three different conditioning regimens","volume":"25","author":"Maymani","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.028_bib0055","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.bbmt.2018.11.001","article-title":"Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","volume":"25","author":"Holstein","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bbmt.2020.03.028_bib0056","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.bbmt.2019.09.015","article-title":"Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","volume":"26","author":"Holstein","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bbmt.2020.03.028_bib0057","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2017.12.774","article-title":"BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: summary and recommendations from the organizing committee","volume":"24","author":"Holstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bbmt.2020.03.028_bib0058","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: a voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.028_bib0059","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.bbmt.2018.12.002","article-title":"The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma","volume":"25","author":"Hagen","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.03.028_bib0060","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.bbmt.2018.11.009","article-title":"The future of chimeric antigen receptor T cell therapy for the treatment of multiple myeloma","volume":"25","author":"Cornell","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bbmt.2020.03.028_bib0061","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41409-019-0674-2","article-title":"Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA-CAR-T therapy in patient with relapsed myeloma","volume":"55","author":"Lin","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:12:03Z","timestamp":1761059523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120302184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1083879120302184"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.028","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}